secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2023-09-22T23:59:59+00:00
Accession:  0001125345-23-000113
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics amends TZIELD royalty deal; retains $50M sales milestone and 50% royalty share
--------------------------------------------------------------------------------

- Terminated Royalty Purchase Agreement with DRI; Aventis (Sanofi sub) now receives royalty directly from Provention Bio.
- Asset Purchase Agreement amended to include $50M milestone payment from Sanofi if TZIELD net sales hit certain level.
- MacroGenics retains 50% royalty on global TZIELD sales above an annual threshold.
- Sanofi guarantees the $50M sales milestone obligation to MacroGenics.
- All prior obligations under the Royalty Purchase Agreement eliminated as of September 19, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534523000113/0001125345-23-000113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534523000113/mgnx-20230919.htm
  HTML page:      https://secwatch.observer/filing/0001125345-23-000113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer